Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Gastro-enteropancreatic neuroendocrine tumor 2Pheochromocytoma 1Paraganglioma 1Oncogenic osteomalacia 1Metastatic Neuroendocrine Prostate Cancer 1Meningioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Medullary 1Carcinoid Tumor 1

Interventions

vandetanib 2cabozantinib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Everolimus 2veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1sargramostim 1pentetreotide 1mercaptoundecahydrododecaborate 1gallium Ga 68 dotatate 1fludarabine 1cixutumumab 1Vinorelbine 1Temozolomide 1Specimen Handling 1Sirolimus 1Semaxinib 1Salts 1Ranitidine 1Paclitaxel 1Omeprazole 1Octreotide 1Nivolumab 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Medullary × gallium Ga 68 dotatate × Clear all
NCT06520319 2024-07-25

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma

First Affiliated Hospital of Fujian Medical University

Phase 1 Recruiting
20 enrolled

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡